Ratings Jubilant Ingrevia Limited Bombay S.E.

Equities

JUBLINGREA

INE0BY001018

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-04-29 EDT			5-day change	1st Jan Change
542.2 ^INR	-0.32%		+0.78%	+6.85%

04-26	Jubilant Ingrevia Raises INR1 Billion Via Commercial Paper Issue	MT
04-17	Jubilant Ingrevia Issues Commercial Papers Worth INR1 Billion	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With an expected P/E ratio at 42.96 and 27.02 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialty Chemicals

	1st Jan change	Capi.	ESG Refinitiv
JUBILANT INGREVIA LIMITED	+6.85%	1.04B	B
ECOLAB INC.	+11.85%	63.22B	A-
SIKA AG	-3.51%	46.34B	A-
GIVAUDAN SA	+13.09%	39.97B	B+
FUJIFILM HOLDINGS CORPORATION	+17.83%	25.46B	A-
EMS-CHEMIE HOLDING AG	+8.37%	18.68B	C+
CELANESE CORPORATION	+0.95%	17.24B	B+
POSCO FUTURE M CO., LTD.	-20.33%	15.81B	A-
SYMRISE AG	+0.36%	14.9B	B+
ALBEMARLE CORPORATION	-13.35%	13.74B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes